Two New Drugs for Chronic Hepatitis CAschenbrenner, Diane S. MS, RNAJN The American Journal of Nursing: September 2011 - Volume 111 - Issue 9 - p 22 doi: 10.1097/01.NAJ.0000405053.00454.26 Drug Watch Abstract Author Information Two new protease inhibitors that specifically target the hepatitis C virus have recently been approved: telaprevir (Incivek) and boceprevir (Victrelis). Both drugs are added to standard chronic hepatitis C treatment to improve the therapeutic response; they're not used as monotherapy. Food containing 20 g of fat must be eaten 30 minutes before taking telaprevir. Boceprevir can be taken just before, during, or just after a meal, with no dietary restrictions. Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: firstname.lastname@example.org. © 2011 Lippincott Williams & Wilkins, Inc.